JNJ vs MRK — which stock performed better?

Johnson & Johnson (JNJ) versus Merck & Co., Inc. (MRK), Health Care, on 2026-08-19.

Result

Merck & Co., Inc. (MRK) performed better on 2026-08-19. JNJ moved -0.130%, MRK moved 11.560%.

Why these two companies

Two of the largest names in Big Pharma are riding parallel momentum into this session: Johnson & Johnson traded within about 2% of its 52-week high of $274.90 on the afternoon of August 18, 2026, per a same-day report on its record-adjacent levels, while Merck notched a fresh 52-week high of $137.98 that same day after a wave of sell-side upgrades. Both companies just raised full-year 2026 guidance off strong Q2 prints, setting up a genuine question of which blue-chip drugmaker carries more short-term momentum.

The research

Johnson & Johnson makes everything from cancer drugs and vaccines to surgical robots and medical devices, while Merck focuses more narrowly on prescription medicines, especially its huge cancer drug Keytruda and its Gardasil vaccine. Both companies just told investors their businesses are doing better than expected and raised their profit expectations for the rest of the year, which is why both stocks have been climbing toward new highs recently.

One reason to like Johnson & Johnson is that it has many different businesses working at once, so if one area slows down, others can pick up the slack. One reason to like Merck is that it has had a wave of positive attention from Wall Street analysts this week, with several raising their price expectations for the stock.

One thing to watch with Johnson & Johnson is that it's still dealing with some ongoing lawsuits and the loss of sales from an older drug facing cheaper copycat competition. One thing to watch with Merck is that a very large share of its business depends on just one or two big-selling drugs, so any bad news about those specific products could hit the stock harder than it would hit a more spread-out company like J&J.

Both are large, well-known healthcare companies that tend to move less dramatically than smaller or newer stocks, so this matchup is really about which giant has a bit more spring in its step heading into the next trading session.